It's a big loss but it's not out of line with what pre-revenue clinical-stage pharmas burn. I've thought that 25 million shares fully diluted at commercialization seems like a reasonable amount and with 17.5 million shares fully diluted, another 7.5 million shares issued at an average of $30 would raise $225 million, which should be more than enough to get to TAVR commercial revenue even with things usually taking longer than expected and costing more than expected.
Ann: Appendix 4D and Half Year Financial Report, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1119 | $6.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 280 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |